Everest Medicines Limited (1952.HK)

HKD 50.8

(3.15%)

Long Term Debt Summary of Everest Medicines Limited

Everest Medicines Limited's latest annual long term debt in 2023 was 469.31 Million CNY , up 691.32% from previous year.
Everest Medicines Limited's latest quarterly long term debt in 2024 Q1 was - CNY , down -100.0% from previous quarter.
Everest Medicines Limited reported annual long term debt of 59.3 Million CNY in 2022, down -87.02% from previous year.
Everest Medicines Limited reported annual long term debt of 456.78 Million CNY in 2021, up 6.65% from previous year.
Everest Medicines Limited reported quarterly long term debt of 497.92 Million CNY for 2023 Q3, up 82.78% from previous quarter.
Everest Medicines Limited reported quarterly long term debt of 469.31 Million CNY for 2023 FY, up 691.32% from previous quarter.

Annual Long Term Debt Chart of Everest Medicines Limited (2023 - 2018)

Historical Annual Long Term Debt of Everest Medicines Limited (2023 - 2018)

Year	Long Term Debt	Long Term Debt Growth
2023	469.31 Million CNY	691.32%
2022	59.3 Million CNY	-87.02%
2021	456.78 Million CNY	6.65%
2020	428.31 Million CNY	1317.51%
2019	30.21 Million CNY	176.75%
2018	10.91 Million CNY	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	- CNY	-100.0%
2023 Q3	497.92 Million CNY	82.78%
2023 FY	469.31 Million CNY	691.32%
2023 Q4	469.31 Million CNY	-5.75%
2023 Q2	272.42 Million CNY	-12.14%
2023 Q1	310.05 Million CNY	422.8%
2022 Q4	59.3 Million CNY	-34.27%
2022 Q3	90.23 Million CNY	7.37%
2022 Q2	84.03 Million CNY	-26.35%
2022 Q1	114.1 Million CNY	-75.02%
2022 FY	59.3 Million CNY	-87.02%
2021 Q3	483.56 Million CNY	17.68%
2021 Q2	410.91 Million CNY	-5.53%
2021 Q1	434.94 Million CNY	-3.17%
2021 FY	456.78 Million CNY	6.65%
2021 Q4	456.78 Million CNY	-5.54%
2020 Q4	449.19 Million CNY	0.0%
2020 Q1	31.14 Million CNY	0.0%
2020 Q3	449.19 Million CNY	0.0%
2020 Q2	- CNY	-100.0%
2020 FY	428.31 Million CNY	1317.51%
2019 FY	30.21 Million CNY	176.75%
2019 Q1	- CNY	0.0%
2018 FY	10.91 Million CNY	0.0%

Peer Long Term Debt Comparison of Everest Medicines Limited

Name	Long Term Debt	Long Term Debt Difference
Uni-Bio Science Group Limited	30.61 Million HKD	-1433.092%
CK Life Sciences Int'l., (Holdings) Inc.	4.27 Billion HKD	89.017%